{
  "drug_name": "Ticagrelor",
  "url": "https://wikem.org/wiki/Ticagrelor",
  "scraped_at": "2026-01-10T08:03:37.800043",
  "sections": {
    "General": {
      "text": "Type:\nAntiplatelet\nDosage Forms: Pill\nCommon Trade Names: Brilenta",
      "subsections": {},
      "tables": [],
      "links": [
        {
          "text": "Antiplatelet",
          "url": "https://wikem.org/wiki/Antiplatelet"
        }
      ]
    },
    "Adult_Dosing": {
      "text": "ACS: 180mg (two 90mg tablets) loading dose\nPO vs OG vs NG (depending on mental status)\nACS patients who have received a loading dose of\nClopidogrel\nmay be started on Ticagrelor\nMaintenance: 90mg twice daily",
      "subsections": {},
      "tables": [],
      "links": [
        {
          "text": "Clopidogrel",
          "url": "https://wikem.org/wiki/Clopidogrel"
        }
      ]
    },
    "Pediatric_Dosing": {
      "text": "Undetermined",
      "subsections": {},
      "tables": [],
      "links": []
    },
    "Special_Populations": {
      "text": "Pregnancy Rating\n: Category C\nLactation: Undetermined\nRenal Dosing\nAdult\nNo adjustment necessary\nPediatric\nHepatic Dosing\nAdult\nMild impairment - no adjustment necessary\nModerate impairment - not defined but use caution as undergoes hepatic metabolism\nSevere impairment - avoid use\nPediatric",
      "subsections": {},
      "tables": [],
      "links": [
        {
          "text": "Pregnancy Rating",
          "url": "https://wikem.org/wiki/Drug_Ratings_in_Pregnancy"
        }
      ]
    },
    "Contraindications": {
      "text": "Allergy to class/drug\nHistory of:\nIntracranial hemorrhage\nActive pathological bleeding, such as peptic ulcer or intracranial hemorrhage\nSevere hepatic impairment",
      "subsections": {},
      "tables": [],
      "links": []
    },
    "Adverse_Reactions": {
      "text": "",
      "subsections": {
        "Serious": {
          "text": "Major coronary artery bypass graft (CABG)–related bleeding (86%)\n[1]\nDigoxin: Because of inhibition of the P-gp transporter, digoxin concentrations may be elevated, increasing the risk of toxicity.\nMonitor digoxin concentrations with initiation of, or any change in, ticagrelor therapy",
          "tables": []
        },
        "Common": {
          "text": "Cardiovascular\nVentricular pause (6%)\nAtrial fibrillation\nHypertension (4%)\nChest pain\nHypotension\n(3%)\nCNS\nHeadache (7%)\nDizziness (5%)\nFatigue (3%)\nSyncope/pre-syncope/loss of consciousness (2%)\nGI\nDiarrhea\n, nausea (4%).\nHematologic\nNon–CABG-related bleeding (9%)\nPulmonary\nDyspnea (14%)\nCough (5%)",
          "tables": []
        }
      },
      "tables": [],
      "links": [
        {
          "text": "Chest pain",
          "url": "https://wikem.org/wiki/Chest_pain"
        },
        {
          "text": "Hypotension",
          "url": "https://wikem.org/wiki/Hypotension"
        },
        {
          "text": "Diarrhea",
          "url": "https://wikem.org/wiki/Diarrhea"
        }
      ]
    },
    "Serious": {
      "text": "Major coronary artery bypass graft (CABG)–related bleeding (86%)\n[1]\nDigoxin: Because of inhibition of the P-gp transporter, digoxin concentrations may be elevated, increasing the risk of toxicity.\nMonitor digoxin concentrations with initiation of, or any change in, ticagrelor therapy",
      "subsections": {
        "Common": {
          "text": "Cardiovascular\nVentricular pause (6%)\nAtrial fibrillation\nHypertension (4%)\nChest pain\nHypotension\n(3%)\nCNS\nHeadache (7%)\nDizziness (5%)\nFatigue (3%)\nSyncope/pre-syncope/loss of consciousness (2%)\nGI\nDiarrhea\n, nausea (4%).\nHematologic\nNon–CABG-related bleeding (9%)\nPulmonary\nDyspnea (14%)\nCough (5%)",
          "tables": []
        }
      },
      "tables": [],
      "links": [
        {
          "text": "Chest pain",
          "url": "https://wikem.org/wiki/Chest_pain"
        },
        {
          "text": "Hypotension",
          "url": "https://wikem.org/wiki/Hypotension"
        },
        {
          "text": "Diarrhea",
          "url": "https://wikem.org/wiki/Diarrhea"
        }
      ]
    },
    "Common": {
      "text": "Cardiovascular\nVentricular pause (6%)\nAtrial fibrillation\nHypertension (4%)\nChest pain\nHypotension\n(3%)\nCNS\nHeadache (7%)\nDizziness (5%)\nFatigue (3%)\nSyncope/pre-syncope/loss of consciousness (2%)\nGI\nDiarrhea\n, nausea (4%).\nHematologic\nNon–CABG-related bleeding (9%)\nPulmonary\nDyspnea (14%)\nCough (5%)",
      "subsections": {},
      "tables": [],
      "links": [
        {
          "text": "Chest pain",
          "url": "https://wikem.org/wiki/Chest_pain"
        },
        {
          "text": "Hypotension",
          "url": "https://wikem.org/wiki/Hypotension"
        },
        {
          "text": "Diarrhea",
          "url": "https://wikem.org/wiki/Diarrhea"
        }
      ]
    },
    "Pharmacology": {
      "text": "Half-life: 7 hours (ticagrelor) and 9 hours (active metabolite)\nMetabolism: liver (CYP3A4)\nExcretion: 26% excreted in urine (less than 1% as ticagrelor and the active metabolite); 58% excreted in feces\nMechanism of Action: Reversibly binds to the P2Y 12 class of adenosine diphosphate (ADP) receptors on platelets to prevent signal transduction and platelet activation",
      "subsections": {},
      "tables": [],
      "links": []
    },
    "See_Also": {
      "text": "Antiplatelet medications\nAntiplatelet agent reversal",
      "subsections": {},
      "tables": [],
      "links": [
        {
          "text": "Antiplatelet medications",
          "url": "https://wikem.org/wiki/Antiplatelet_medications"
        },
        {
          "text": "Antiplatelet agent reversal",
          "url": "https://wikem.org/wiki/Antiplatelet_agent_reversal"
        }
      ]
    },
    "References": {
      "text": "Ticagrelor: Drug information. UpToDate. www.uptodate.com. Accessed April 2, 2019.",
      "subsections": {},
      "tables": [],
      "links": []
    }
  }
}